What changed in ResMed Inc.'s latest annual report
In the year ended 30 Jun 2026, ResMed Inc.'s revenue rose 9.9% to USD 5.65bn, from USD 5.15bn; net income rose 8.8% to USD 1.52bn, from USD 1.40bn; long-term debt fell 39.3% to USD 399.42m, from USD 658.39m.
Year ended 30 Jun 2026. Source: 10-K filed 13 Aug 2026, read it on SEC EDGAR.
USD 5.15bn to USD 5.65bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 5.15bn | 5.65bn | Up 9.9% |
| Net income | 1.40bn | 1.52bn | Up 8.8% |
| Total assets | 8.17bn | 8.97bn | Up 9.7% |
| Total liabilities | 2.21bn | 2.38bn | Up 7.9% |
| Long-term debt | 658.39m | 399.42m | Down 39.3% |
| Cash and cash equivalents | 1.21bn | 1.47bn | Up 21.5% |
| Shareholders' equity | 5.97bn | 6.59bn | Up 10.3% |
Questions people ask
Did ResMed Inc.'s revenue grow last year?
Revenue grew 9.9%, from USD 5.15bn to USD 5.65bn in the year ended 30 Jun 2026.
Is ResMed Inc. profitable?
Yes. Net income was USD 1.52bn in the year ended 30 Jun 2026. The year before: USD 1.40bn.
How much cash and debt does ResMed Inc. have?
At its latest year end (30 Jun 2026), ResMed Inc. reported cash and cash equivalents of USD 1.47bn and long-term debt of USD 399.42m.
Where do these numbers come from?
From ResMed Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with ResMed Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- 3M CompanyShareholders' equity up 22.4%
- Boston Scientific CorporationCash and cash equivalents up 374.6%
- Becton, Dickinson And CompanyCash and cash equivalents down 62.7%
- Medline Inc.Cash and cash equivalents up 874.4%
- Dexcom, Inc.Cash and cash equivalents up 51.4%
- West Pharmaceutical Services, Inc.Cash and cash equivalents up 63.3%
- Solventum CorporationNet income up 224.8%